Allogene Therapeutics
Chelsea Williams is an accomplished professional in clinical operations with extensive experience in various leadership roles within the pharmaceutical and clinical research industries. Current positions include Director of Clinical Operations at Allogene Therapeutics and President at RISE Clinical Research, LLC. Previous roles encompass Associate Director at Bayer Pharmaceuticals and Manager of Clinical Operations at PRA Health Sciences, with a focus on oncology and hematology. Chelsea started as a Senior Clinical Research Associate, demonstrating a robust foundation in clinical research operations. Chelsea is pursuing a Doctor of Public Health at Capella University, expected to be completed in March 2024, and has enhanced leadership skills through a Women in Leadership program at Cornell University.
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.